home.aspx
 
. https://pharmaceutical.report/Resources/Whitepapers/93f2034b-65e8-4bdb-880f-2c2e476d3b04_media-release-pdf.pdf
infographic
SHARESHARESHARE
NOVARTIS PRESENTS FIRST-OF-ITS-KIND ALGORITHM
Novartis today announced results from a validation study of the innovative, algorithm-based digital solution MS Progression Discussion Tool, or MSProDiscussTM. The tool aims to support and facilitate a discussion between physicians and patients living with multiple sclerosis (MS) who have transitioned, or are at risk of transitioning from relapsing remitting MS (RRMS) to secondary progressive MS (SPMS). Diagnosing SPMS can be challenging but if carried out in a timely manner, could help to prevent further irreversible damage3 . The study findings, presented today at the 2019 American Academy of Neurology Annual Meeting (AAN) in Philadelphia, Pennsylvania, USA, support the validity and potential use of MSProDiscuss™ to help evaluate and discuss early signs suggestive of progression in clinical practice. DOWNLOAD